Alexander Light

NIHR Doctoral Fellow @IP_London @NIHRresearch | Urology registrar @NorthLonUrol | @Packers owner | 🇬🇧🇲🇾🇨🇳

[Alexander Light @AJWLight]

A career highlight to lead this study on 10 year outcomes in almost 3500 men undergoing focal therapy, now published in @EUplatinum

And fantastic to see the widespread UK media coverage today across TV, radio, and print!

Many thanks to my collaborators and mentors 🙏

[Imperial Prostate @IP_London]

🚨 NEW IN @EUplatinum! 🚨

The largest analysis of focal therapy by Imperial Prostate and UK colleagues, reporting 1⃣0⃣-year outcomes after focal HIFU and cryotherapy in 3⃣4⃣7⃣7⃣ men 🔥🧊

Led by @AJWLight @LondonProstate1 @TaimurShah

Read for free: https://t.co/BL19aINTgM

[Imperial Prostate @IP_London]

The #RADAR Study is now open!🚨

High risk men aged 40-49 will have a #Prostagram scan, a Stockholm3 test, and a PSA test to find the best way to screen for #ProstateCancer. Check if you can sign up here: https://t.co/iKG73JmeVP

@NIHRresearch @ImperialSandC @ImperialNHS

[Nikhil Mayor @NikhilMayor]

Absolutely delighted to launch the #RADAR study at @ImperialNHS to #screen younger, but higher risk men for #ProstateCancer. All men get 3 advanced tests on the same day - express your interest here: https://t.co/FeFFIHsa6H

@LondonProstate1 @IP_London @NIHRresearch

[Alexander Light @AJWLight]

@TylerSbrt @LondonProstate1 A big reason to have a pre-ablation DCE available is to compare it to post-ablation scans, given DCE thought by many to be the key sequence for detecting in-field recurrences. But some argue any post-ablation enhancement = suspicious regardless of initial MRI, so bp is sufficient

[Alexander Light @AJWLight]

Interesting

TARGET international consensus guidance - we had uncertainty as to whether the pre-treatment MRI needs DCE (Eur Urol 2024; https://t.co/fBhfJAvYfx)

But PI-FAB, published by the same institution as PRIME, requires comparison with the pre-treatment DCE images 🤷

[Wei Phin Tan, MD, MHS, FACS @DrTanWP]

Great point-counterpoint at the podium today: @veerukasi arguing biparametric MRI should be the new standard of care for prostate cancer diagnosis vs @RaisBahrami making the case to keep contrast. PRIME (JAMA 2025) says bpMRI is noninferior to mpMRI for csPCa (29.0% vs 29.6%, 555 men, 22 centers). Shorter scan, no gadolinium. The counterargument: DCE still helps with equivocal PI-RADS 3 lesions and better defines lesion size, which matters for focal therapy planning. Where do you land? @FocalSociety @Endo_Society #ProstateCancer #bpMRI #PRIMEtrial #FTS2026 @JAMA_current

[Imperial Prostate @IP_London]

New milestone reached!
IP10-AVIDITY has now recruited over 50 patients.
Congratulations to @royalmarsdenNHS for recruiting the 50th patient 👏

[Patrick Gomella MD, MPH, FACS @PGomellaMD]

PSA to all my urologic cancer colleagues. Stop personally treating PCa. We should refer all prostate pts to @EvanThomas84. His outcomes are "perfect." NEVER has had a patient with urinary issues after prostate radiation. In fact they have better function.

[Patrick Gomella MD, MPH, FACS @PGomellaMD]

Radiation oncologists against any other treatment option: "We need data!". "Urologists are charlatans and bad surgeons!". Also their rebuttals include anecdotal comments about their overflowing clinics filled with endless focal therapy disasters.

[Dong Nguyen @DongNguyeb]

We have just read a Letter to the Editor from @nickva1, @alison_tree, @piet_ost that carries an implication of dishonesty, and unfaith, deliberately distorting the facts in order to criticize and mislead readers to truly understand the article .

“Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries”

We firmly oppose their behavior. Our forthcoming analysis will clarify the actual content and specifically identify how they have twisted the information.

@LondonProstate1 ,@AJWLight @IP_London

[Patrick Gomella MD, MPH, FACS @PGomellaMD]

@EvanThomas84 Never and always are two words that should not be used in discussions with patients. I'll await your published 12-15 year oncologic and functional outcome from your personal prostate cancer panel showing 100%cancer control, 0%BCR and improved IPSS and SHIMs

[Imperial Prostate @IP_London]

🎉 Delighted to welcome Sunderland Royal Hospital (@mccrackenstuart, Fraser Barbour) & @FreemanHospital (@rajan_vpillay, James Leighton) to #IP16SCOPE, an international service evaluation on #ActiveSurveillance in #ProstateCancer!
📩Interested? Email us: [email protected]

[Imperial Prostate @IP_London]

🚨NEW PUBLICATION🚨
IB1-LASERCOMPLETE live in @BJUIjournal!
@TUF funded prospective feasibility study in bladder cancer:
👉 Can FCM help detrusor muscle detection in TURBT samples
📄 Read it free: https://t.co/bm6QC67jT4
Thank you to the funder, all co-authors and the patients!

[Imperial Prostate @IP_London]

@Archana_GK1 presented RAPID 5-year #ActiveSurveillance outcomes at @SGU2026 in St Gallen

➡️ ~50% treatment within 5 years, GG2>GG1
➡️ Treatment triggers are heterogenous
➡️ Active surveillance needs improvement
➡️ IP9-ATLAS RCT recruiting (MRI-guided vs NICE SOC surveillance)

[Imperial Prostate @IP_London]

Great presentation of the #IB1LASERCOMPLETE results looking at #FCM for detrusor muscle detection in TURBT samples by @Archana_GK1 at #SGU2026 (St Gallen)

✅ 100% feasible to interpret FCM images
✅ High inter-observer agreement
🔍 Exploratory diagnostic performance unclear

[European Urology @EUplatinum]

📢 New publication in European Urology

We are pleased to highlight a new study published in European Urology, titled “Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway”.

👏 Congratulations to Chase Ng, Alexander Light, and Taimur Shah on this excellent contribution, together with all co-authors.

🔗 Read the full article here:
👉 https://t.co/qh9oFflmmE

#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

[Alexander Light @AJWLight]

Wholeheartedly recommend applying!!

[Imperial Prostate @IP_London]

📣 Calling all aspiring academic urologists: we are hiring!

Applications open soon for the 2027 @NIHRresearch Academic Clinical Fellowship in urology.

Join our 🌍-leading #ProstateCancer research group led by @LondonProstate1 💫

https://t.co/bHUuoguQwl

[Alexander Light @AJWLight]

@Cwechris @RSanchez_Salas It also includes whole gland ablation and salvage ablation in unknown (but likely significant) quantities, which really undermines it

The limitations paragraph includes the confusing sentence “we were also not able to distinguish between partial and whole gland focal therapy”

[Hashim U. Ahmed @LondonProstate1]

Presumably SBRT for localised favourable intermediate PCa will be rolled back following this RCT of 698 patients randomised in 136 international centres; designed and powered a priori as superiority of cancer control for SBRT over MH-IMRT, but wasn’t?

https://t.co/GipkaM1C4A

[Alexander Light @AJWLight]

Fantastic trial that will provide definitive evidence for bpMRI vs mpMRI, and fusion versus cognitive biopsy!

[Imperial Prostate @IP_London]

#IP7 #PACIFIC has recruited its 2️⃣0️⃣0️⃣0️⃣th patient! Well done to all sites involved, and to Southend @MSEHospitals who recruited patient number 2000!

Not long to go!

[Hashim U. Ahmed @LondonProstate1]

📣Congratulations to Nikhil Mayor! Former Academic Clinical Fellow in Urology, currently Transform study’s Clinical Research Fellow and now an NIHR Doctoral Fellow with £0.5M awarded to him

🎉Amazing achievement!!